Intravitreal Bevacizumab for Age-Related Macular Degeneration

Age Related Macular Degeneration Clinical Trial

Official title:

Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00347165
• Other study ID #: AvastinDMRE
• Status: Terminated
• Phase: Phase 2
• Start date: September 2005
• Est. completion date: September 2006

Study information

• Verified date: May 2024
• Source: Asociación para Evitar la Ceguera en México
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration

Description:

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined.

The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: September 2006
• Est. primary completion date: June 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 99 Years

Eligibility

Inclusion Criteria:

• age >50 age related macular degeneration

Exclusion Criteria:

• moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• Macular Degeneration

Intervention

Drug:
• bevacizumab intravitreal injection

Locations

Country	Name	City	State
Mexico	Hospital Luis Sanchez Bulnes	MExico city	DF

Sponsors (1)

Lead Sponsor	Collaborator
Asociación para Evitar la Ceguera en México

Country where clinical trial is conducted

Mexico, 

References & Publications (1)

Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of visual acuity at 6 months
Secondary	Retinal thickness at 6 months
Secondary	Leakiness in fluorangiography at 6 months